Sciele Pharma, Inc. and Plethora Solutions Holdings Announce Positive Results of Final Phase III Pivotal Trial for PSD502 for Premature Ejaculation

ATLANTA--(BUSINESS WIRE)--Sciele Pharma Inc.: Sciele Pharma Inc., a Shionogi Company, and Plethora Solutions Holdings PLC (“Plethora” – AIM:PLE), today announced that a second and final Phase III double-blind, placebo-controlled study of PSD502 for the treatment of premature ejaculation (‘PE’) has met all co-primary endpoints of Intra-vaginal Ejaculation Latency Time (‘IELT’), Index of Premature Ejaculation (‘IPE,’ Ejaculatory Control, Sexual Satisfaction and Distress domains).